Obsidian Therapeutics, Inc. Announces Presentation of Preclinical Data on its Technology Platform and Applications
Feb 13 18
Obsidian Therapeutics, Inc. announced the presentation of preclinical data on its technology platform and applications at the Keystone Symposium on Emerging Cellular Therapies. The presentation includes initial in vivo proof of concept data demonstrating Obsidian’s strategy for precise pharmacologic control of cell therapy by employing destabilizing domains (DDs), which are small, fully-human protein domains that confer conditional stability to a fused payload protein. The Keystone presentation describes the successful implementation of DD technology in engineered primary human T cells and demonstrates ligand-controlled regulation of cytokine protein expression in vitro and in vivo to enhance CAR-T function. These data demonstrate the feasibility of exogenous control over transgene-derived protein expression in primary human T cells for the development of next-generation CAR-T cell products with enhanced efficacy and more favorable safety profiles. Data presented at the meeting include: - Destabilizing domain (DD) technology enabled titratable and reversible regulation of protein levels in preclinical studies, using FDA-approved small-molecule drugs as pharmacologic regulators. - The studies demonstrated small-molecule control of DD-mbIL15 and DD-IL12 “cassettes” in human T cells in vitro. - Systemic IL12 levels from transduced T cells were regulated in vivo with pulsatile dosing and precise dose-response. - A range of DD variants were used in the studies, with performance characteristics matched to specific applications. - These studies represent in vivo proof of concept for the ability to create next-generation CAR-T cell products that provide precise control over transgene-derived protein expression, with the potential to offer enhanced efficacy and more favorable safety profiles.
Obsidian Therapeutics, Inc. Presents at Keystone Symposia Conference, Feb-11-2018
Feb 13 18
Obsidian Therapeutics, Inc. Presents at Keystone Symposia Conference, Feb-11-2018 . Venue: Keystone Resort, Keystone, Colorado, United States.
Obsidian Therapeutics Announces Management Changes
Dec 6 17
Obsidian Therapeutics, Inc. named Michael Gilman, Ph.D., as Chief Executive Officer. The company has assembled a strong scientific team: Michael Gilman, Ph.D., CEO of Obsidian Therapeutics, CEO of Arrakis Therapeutics, former founding CEO of Padlock Therapeutics and Stromedix, with executive roles at Biogen and ARIAD Pharmaceuticals; Tariq Kassum, M.D., Senior Vice President, Head of Business Operations, and company cofounder, former leadership roles at Takeda and Millennium Pharmaceuticals; Steve Shamah, Ph.D., Senior Vice President and Head of Research, former leadership roles at Juno Therapeutics and X-Body Biosciences; Vipin Suri, Ph.D., Vice President, Head of Discovery, and company cofounder, former roles at Raze Therapeutics and GSK; Celeste Richardson, Ph.D., Vice President, Cell Therapy, former roles at Novartis Institute for Biomedical Research. The company’s Board of Directors includes: Peter Barrett, Ph.D., Partner at Atlas Venture; Karen Hong, Ph.D., Senior Investment Director at Takeda Ventures, Inc.; Carolyn Ng, Ph.D., Principal, Vertex Ventures HC; Jason Gardner, Ph.D., CEO of Magenta Therapeutics; Michael Gilman, Ph.D., CEO of Obsidian Therapeutics. Observers on the Board of Directors are Blake Byers, Ph.D., General Partner at GV; Michael Gladstone, Principal at Atlas Venture; and Gladys Nunez, M.Sc., Principal, Amgen Ventures.